Digitally Immune Optimised Synthetic Vaccines
Invivyd working with FDA towards potential Biologics License Application for COVID-19
The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive
Kostaive is designed to instruct the body to make more mRNA to boost immune response
UK drug repurposing study identifies several potential dementia treatments
An estimated 982,000 people in the UK are currently living with the neurodegenerative disease
WHO urges US to ‘reconsider’ withdrawal from global health organisation
President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises
Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines
The combined vaccine approach could simplify immunisation practices and lead to higher uptake
Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults
Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19
Seven strategic steps to enhance patient recruitment & retention in your influenza studies
The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...
Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study
The serious adverse event reported was found to be unrelated to the vaccine
Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation
The updated vaccine was shown to generate an improved response against currently circulating variants
Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children
The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme